Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 3
2005 6
2006 5
2007 4
2008 8
2009 9
2010 5
2011 12
2012 10
2013 19
2014 17
2015 13
2016 17
2017 11
2018 19
2019 13
2020 9
2021 17
2022 12
2023 9
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Results by year

Filters applied: . Clear all
Page 1
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial.
Satti I, Marshall JL, Harris SA, Wittenberg R, Tanner R, Lopez Ramon R, Wilkie M, Ramos Lopez F, Riste M, Wright D, Peralta Alvarez MP, Williams N, Morrison H, Stylianou E, Folegatti P, Jenkin D, Vermaak S, Rask L, Cabrera Puig I, Powell Doherty R, Lawrie A, Moss P, Hinks T, Bettinson H, McShane H. Satti I, et al. Among authors: mcshane h. Lancet Infect Dis. 2024 Apr 12:S1473-3099(24)00143-9. doi: 10.1016/S1473-3099(24)00143-9. Online ahead of print. Lancet Infect Dis. 2024. PMID: 38621405
Revaccination with BCG: does it work?
McShane H. McShane H. Lancet Infect Dis. 2024 Feb 26:S1473-3099(24)00006-9. doi: 10.1016/S1473-3099(24)00006-9. Online ahead of print. Lancet Infect Dis. 2024. PMID: 38423022 No abstract available.
Deficiency of factor-inhibiting HIF creates a tumor-promoting immune microenvironment.
Ma J, Al Moussawi K, Lou H, Chan HF, Wang Y, Chadwick J, Phetsouphanh C, Slee EA, Zhong S, Leissing TM, Roth A, Qin X, Chen S, Yin J, Ratnayaka I, Hu Y, Louphrasitthiphol P, Taylor L, Bettencourt PJG, Muers M, Greaves DR, McShane H, Goldin R, Soilleux EJ, Coleman ML, Ratcliffe PJ, Lu X. Ma J, et al. Among authors: mcshane h. Proc Natl Acad Sci U S A. 2024 Mar 5;121(10):e2309957121. doi: 10.1073/pnas.2309957121. Epub 2024 Feb 29. Proc Natl Acad Sci U S A. 2024. PMID: 38422022 Free PMC article.
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control.
Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Powell Doherty R, Marshall JL, Cabrera Puig I, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM; TB042 Study Team. Wajja A, et al. Among authors: mcshane h. Lancet Infect Dis. 2024 Feb;24(2):e78-e79. doi: 10.1016/S1473-3099(23)00758-2. Epub 2024 Jan 3. Lancet Infect Dis. 2024. PMID: 38184003 No abstract available.
Exploring the ethics of tuberculosis human challenge models.
Rohrig A, Morrison J, Kleinwaks G, Pugh J, McShane H, Savulescu J. Rohrig A, et al. Among authors: mcshane h. J Med Ethics. 2023 Dec 30:jme-2023-109234. doi: 10.1136/jme-2023-109234. Online ahead of print. J Med Ethics. 2023. PMID: 38159935 Free article.
Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.
Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Doherty RP, Marshall JL, Puig IC, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM; TB042 Study Team. Wajja A, et al. Among authors: mcshane h. Lancet Infect Dis. 2024 Mar;24(3):285-296. doi: 10.1016/S1473-3099(23)00501-7. Epub 2023 Nov 25. Lancet Infect Dis. 2024. PMID: 38012890 Free article. Clinical Trial.
200 results